Minoryx Therapeutics
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | 1.8m | 4.1m | <1m |
| % growth | - | 432 % | 325 % | (80 %) | 3325 % | 121 % | (90 %) |
| EBITDA | (<1m) | (<1m) | (<1m) | (<1m) | <1m | (1.0m) | (<1m) |
| % EBITDA margin | (2240 %) | (947 %) | (41 %) | (1198 %) | 6 % | (25 %) | (238 %) |
| Profit | (<1m) | (1.4m) | (1.4m) | (3.2m) | (<1m) | (5.9m) | (8.3m) |
| % profit margin | (2984 %) | (2199 %) | (509 %) | (5971 %) | (39 %) | (145 %) | (2066 %) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
N/A | Spinout | ||
| N/A | €2.3m | Grant | |
€1.5m | Series A | ||
€1.6m | Early VC | ||
€19.4m | Series A | ||
€3.1m | Grant | ||
* | €21.3m | Series B | |
€25.0m | Grant | ||
* | $25.5m | Debt | |
* | $25.5m | Series C | |
| Total Funding | $107m | ||
Related Content
Recent News about Minoryx Therapeutics
EditMinoryx Therapeutics is a biotechnology startup dedicated to discovering and developing innovative treatments for severe, rare diseases of the central nervous system (CNS). These conditions, often referred to as orphan diseases, have high unmet medical needs, meaning there are few or no effective treatments available. The company is headquartered in Gosselies, Charleroi, Belgium.
Minoryx primarily targets patients suffering from life-threatening neurodegenerative disorders. Their leading program focuses on a compound called leriglitazone, a novel and selective PPAR gamma agonist. This compound is currently in clinical development for multiple orphan CNS disorders, with its primary indication being X-linked Adrenoleukodystrophy (X-ALD), a severe neurodegenerative disease.
The company operates in the biopharmaceutical market, which involves the research, development, and commercialization of drugs. Minoryx's business model revolves around the development and licensing of its proprietary treatments. They generate revenue through partnerships and licensing agreements with other pharmaceutical companies. For instance, Minoryx has an exclusive license agreement with Sperogenix Therapeutics to develop and commercialize leriglitazone in mainland China, Hong Kong, and Macau.
Minoryx has also received significant financial backing to support its research and development efforts. The European Investment Bank has provided substantial funding, and the company has received a fast-track designation from the US FDA for leriglitazone in the treatment of X-ALD. This designation helps expedite the development and review process for drugs that treat serious conditions and fill an unmet medical need.
In summary, Minoryx Therapeutics is at the forefront of developing breakthrough therapies for rare CNS diseases, aiming to bring new hope to patients with limited treatment options.
Keywords: Biotechnology, CNS diseases, Orphan diseases, Neurodegenerative, Leriglitazone, X-ALD, Drug development, Licensing, Clinical trials, FDA fast track.